Akebia Therapeutics, Inc.
AKBA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $160 | $195 | $292 | $212 |
| % Growth | -17.7% | -33.5% | 38.2% | – |
| Cost of Goods Sold | $63 | $74 | $22 | $81 |
| Gross Profit | $97 | $120 | $270 | $130 |
| % Margin | 60.6% | 61.9% | 92.3% | 61.5% |
| R&D Expenses | $38 | $63 | $166 | $148 |
| G&A Expenses | $0 | $0 | $132 | $166 |
| SG&A Expenses | $107 | $100 | $139 | $174 |
| Sales & Mktg Exp. | $0 | $100 | $7 | $8 |
| Other Operating Expenses | $3 | $3 | $46 | $73 |
| Operating Expenses | $147 | $167 | $351 | $395 |
| Operating Income | -$50 | -$46 | -$81 | -$265 |
| % Margin | -31.5% | -23.8% | -27.6% | -125% |
| Other Income/Exp. Net | -$19 | -$6 | -$13 | -$18 |
| Pre-Tax Income | -$69 | -$52 | -$94 | -$282 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$69 | -$52 | -$94 | -$282 |
| % Margin | -43.3% | -26.7% | -32.2% | -133.3% |
| EPS | -0.33 | -0.28 | -0.58 | -1.48 |
| % Growth | -17.9% | 51.7% | 60.8% | – |
| EPS Diluted | -0.33 | -0.28 | -0.58 | -1.48 |
| Weighted Avg Shares Out | 211 | 187 | 183 | 166 |
| Weighted Avg Shares Out Dil | 211 | 187 | 183 | 166 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $18 | $6 | $16 | $20 |
| Depreciation & Amortization | $38 | $38 | $38 | $38 |
| EBITDA | -$14 | -$8 | $3 | -$190 |
| % Margin | -8.6% | -4.2% | 1% | -89.7% |